OBJECTIVE: To determine the associations between classes of antihypertensive medication use and the risk of cognitive impairment among elderly hypertensive men. METHODS: The Honolulu-Asia Aging Study is a prospective, community-based cohort study of Japanese American men conducted in Honolulu, Hawaii. We examined 2,197 participants (mean age 77 years at cohort entry, 1991-1993, followed through September 2010) with hypertension and without dementia or cognitive impairment at baseline, who provided information on medication use. Cognitive function was assessed at 7 standardized examinations using the Cognitive Abilities Screening Instrument (CASI). Cognitive impairment was defined as a CASI score <74. RESULTS: A total of 854 men developed cognitive impairment (median follow-up, 5.8 years). β-Blocker use as the sole antihypertensive drug at baseline was consistently associated with a lower risk of cognitive impairment (incidence rate ratio [IRR] 0.69; 95% confidence interval [CI] 0.50-0.94), as compared with men not taking any antihypertensive medications, adjusting for multiple potential confounders. The use of diuretics, calcium channel blockers, angiotensin-converting enzyme inhibitors, or vasodilators alone was not significantly associated with cognitive impairment. Results were similar excluding those with cardiovascular disease or <1 year of follow-up, and additionally adjusting for pulse pressure, heart rate, baseline and midlife systolic blood pressure, and midlife antihypertensive treatment (IRR 0.65; 95% CI 0.45-0.94). The association between β-blocker use and cognitive impairment was stronger among men with diabetes, men aged >75 years, and those with pulse pressure ≥70 mm Hg. CONCLUSIONS: β-blocker use is associated with a lower risk of developing cognitive impairment in elderly Japanese American men.
OBJECTIVE: To determine the associations between classes of antihypertensive medication use and the risk of cognitive impairment among elderly hypertensivemen. METHODS: The Honolulu-Asia Aging Study is a prospective, community-based cohort study of Japanese American men conducted in Honolulu, Hawaii. We examined 2,197 participants (mean age 77 years at cohort entry, 1991-1993, followed through September 2010) with hypertension and without dementia or cognitive impairment at baseline, who provided information on medication use. Cognitive function was assessed at 7 standardized examinations using the Cognitive Abilities Screening Instrument (CASI). Cognitive impairment was defined as a CASI score <74. RESULTS: A total of 854 men developed cognitive impairment (median follow-up, 5.8 years). β-Blocker use as the sole antihypertensive drug at baseline was consistently associated with a lower risk of cognitive impairment (incidence rate ratio [IRR] 0.69; 95% confidence interval [CI] 0.50-0.94), as compared with men not taking any antihypertensive medications, adjusting for multiple potential confounders. The use of diuretics, calcium channel blockers, angiotensin-converting enzyme inhibitors, or vasodilators alone was not significantly associated with cognitive impairment. Results were similar excluding those with cardiovascular disease or <1 year of follow-up, and additionally adjusting for pulse pressure, heart rate, baseline and midlife systolic blood pressure, and midlife antihypertensive treatment (IRR 0.65; 95% CI 0.45-0.94). The association between β-blocker use and cognitive impairment was stronger among men with diabetes, men aged >75 years, and those with pulse pressure ≥70 mm Hg. CONCLUSIONS: β-blocker use is associated with a lower risk of developing cognitive impairment in elderly Japanese American men.
Authors: K H Masaki; K G Losonczy; G Izmirlian; D J Foley; G W Ross; H Petrovitch; R Havlik; L R White Journal: Neurology Date: 2000-03-28 Impact factor: 9.910
Authors: H Petrovitch; L R White; G Izmirilian; G W Ross; R J Havlik; W Markesbery; J Nelson; D G Davis; J Hardman; D J Foley; L J Launer Journal: Neurobiol Aging Date: 2000 Jan-Feb Impact factor: 4.673
Authors: Michael H Freitag; Rita Peila; Kamal Masaki; Helen Petrovitch; G Webster Ross; Lon R White; Lenore J Launer Journal: Stroke Date: 2005-12-08 Impact factor: 7.914
Authors: Jun Wang; Kenjiro Ono; Dara L Dickstein; Isabel Arrieta-Cruz; Wei Zhao; Xianjuan Qian; Ashley Lamparello; Rakesh Subnani; Mario Ferruzzi; Constantine Pavlides; Lap Ho; Patrick R Hof; David B Teplow; Giulio M Pasinetti Journal: Neurobiol Aging Date: 2010-07-01 Impact factor: 4.673
Authors: Ruth Peters; Nigel Beckett; Francoise Forette; Jaakko Tuomilehto; Robert Clarke; Craig Ritchie; Adam Waldman; Ivan Walton; Ruth Poulter; Shuping Ma; Marius Comsa; Lisa Burch; Astrid Fletcher; Christopher Bulpitt Journal: Lancet Neurol Date: 2008-07-07 Impact factor: 44.182
Authors: Ge Li; Isaac C Rhew; Jane B Shofer; Walter A Kukull; John C S Breitner; Elaine Peskind; James D Bowen; Wayne McCormick; Linda Teri; Paul K Crane; Eric B Larson Journal: J Am Geriatr Soc Date: 2007-08 Impact factor: 5.562
Authors: Amanda N Szabo-Reed; Eric Vidoni; Ellen F Binder; Jeffrey Burns; C Munro Cullum; William P Gahan; Aditi Gupta; Linda S Hynan; Diana R Kerwin; Heidi Rossetti; Ann M Stowe; Wanpen Vongpatanasin; David C Zhu; Rong Zhang; Jeffrey N Keller Journal: Contemp Clin Trials Date: 2019-03-01 Impact factor: 2.226
Authors: Yue-Bin Lv; Peng-Fei Zhu; Zhao-Xue Yin; Virginia Byers Kraus; Diane Threapleton; Choy-Lye Chei; Melanie Sereny Brasher; Juan Zhang; Han-Zhu Qian; Chen Mao; David Bruce Matchar; Jie-Si Luo; Yi Zeng; Xiao-Ming Shi Journal: J Am Med Dir Assoc Date: 2017-02-01 Impact factor: 4.669
Authors: Rebecca F Gottesman; Andrea L C Schneider; Marilyn Albert; Alvaro Alonso; Karen Bandeen-Roche; Laura Coker; Josef Coresh; David Knopman; Melinda C Power; Andreea Rawlings; A Richey Sharrett; Lisa M Wruck; Thomas H Mosley Journal: JAMA Neurol Date: 2014-10 Impact factor: 18.302